HC Wainwright Predicts Stronger Earnings for XOMA Royalty

Key Points

• HC Wainwright has raised its FY2026 earnings per share estimate for XOMA Royalty from $1.16 to $1.34, maintaining a "Buy" rating and setting a price target of $104.00.
• XOMA Royalty recently reported earnings of $0.48 per share for the last quarter, surpassing estimates of a loss of ($0.12) by $0.60 and generating $13.13 million in revenue.
• Several analysts, including Zacks Research and Wall Street Zen, have upgraded XOMA Royalty's stock rating, contributing to a current consensus rating of "Moderate Buy" with an average target price of $69.50.

XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) - Investment analysts at HC Wainwright increased their FY2026 earnings per share estimates for XOMA Royalty in a research note issued on Thursday, August 21st. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of $1.34 for the year, up from their previous estimate of $1.16. HC Wainwright has a "Buy" rating and a $104.00 price target on the stock. The consensus estimate for XOMA Royalty's current full-year earnings is ($1.41) per share.

Other research analysts have also issued research reports about the company. Zacks Research upgraded XOMA Royalty to a "hold" rating in a research report on Tuesday, August 12th. Wall Street Zen upgraded shares of XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Monday, August 11th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $69.50.

XOMA Royalty Stock Up 0.9%

Shares of XOMA opened at $32.75 on Friday. The firm has a market cap of $395.95 million, a P/E ratio of -21.13 and a beta of 1.00. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $35.00. The stock's 50 day moving average is $26.99 and its two-hundred day moving average is $24.52. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 1.41.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The business had revenue of $13.13 million for the quarter, compared to analyst estimates of $9.39 million.

Hedge Funds Weigh In On XOMA Royalty

A number of institutional investors have recently added to or reduced their stakes in XOMA. Tower Research Capital LLC TRC boosted its stake in XOMA Royalty by 203.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,523 shares during the last quarter. Opaleye Management Inc. boosted its position in shares of XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company's stock valued at $6,428,000 after acquiring an additional 2,044 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of XOMA Royalty during the 2nd quarter valued at about $116,000. Occudo Quantitative Strategies LP acquired a new stake in XOMA Royalty during the second quarter worth about $527,000. Finally, Marshall Wace LLP increased its position in XOMA Royalty by 12.2% during the second quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company's stock worth $411,000 after purchasing an additional 1,775 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.